

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008;358:1547-59. DOI: 10.1056/NEJMoa0801317.

## **Appendix 1: Patient Eligibility Criteria**

---

### **Inclusion criteria**

---

Individuals  $\geq 55$  years of age with 1 of the following

Coronary artery disease	Previous myocardial infarction ( $>2$ days post uncomplicated MI) Stable angina or unstable angina $>30$ days with documented evidence of multivessel coronary artery disease Multi-vessel PTCA $>30$ days Multi-vessel CABG surgery $>4$ years, or with recurrent angina following surgery
Peripheral artery disease	Previous limb bypass surgery or angioplasty Previous limb or foot amputation Intermittent claudication, with ankle:arm BP ratio $\leq 0.80$ on at least 1 side Significant peripheral artery stenosis ( $>50\%$ ) documented by angiography or non-invasive testing
Cerebrovascular disease	Previous stroke Transient ischemic attacks $>7$ days and $<1$ year
Diabetes Mellitus	High-risk diabetes with evidence of end-organ damage

---

### **Exclusion criteria**

---

Medication use	Inability to discontinue ACE inhibitors or ARB Known hypersensitivity or intolerance to ACE inhibitors or ARB
Cardiovascular disease	Congestive heart failure Hemodynamically significant valvular or outflow tract obstruction Constrictive pericarditis Complex congenital heart disease Syncope episodes of unknown etiology $<3$ months Planned cardiac surgery or PTCA $<3$ months Uncontrolled hypertension on treatment (eg, BP $>160/100$ mm Hg) Heart transplant recipient Stroke due to subarachnoid hemorrhage
Other conditions	Significant renal artery disease Hepatic dysfunction Uncorrected volume or sodium depletion Primary hyperaldosteronism Hereditary fructose intolerance Other major noncardiac illness or expected to reduce life expectancy or significant disability interfere with study participation Simultaneously taking another experimental drug Unable to provide written informed consent

---